Have a personal or library account? Click to login
Current trends in the risk prediction for hepatitis B virus-related hepatocellular carcinoma Cover

Current trends in the risk prediction for hepatitis B virus-related hepatocellular carcinoma

Asian Biomedicine
Volume 10 (2016): Issue 1 (February 2016)
By: Ken Liu and  Grace Lai-Hung Wong  
Open Access
|Jan 2017

References

  1. 1Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [online] 2013. [cited on 2016 Jan 15]. Available from: http://globocan.iarc.fr
    FerlayJSoerjomataramIErvikMDikshitREserSMathersCet alGLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [online] 2013cited on 2016 Jan 15 Available from http://globocan.iarc.fr
    Back to article
  2. 2Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009; 16:453-63.
    NguyenVTLawMGDoreGJHepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burdenJ Viral Hepat2009 164536310.1111/j.1365-2893.2009.01117.x
    Back to article
  3. 3McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011; 15:223-43, vii-x.
    McGlynnKALondonWTThe global epidemiology of hepatocellular carcinoma: present and futureClin Liver Dis2011 15223–43viix10.1016/j.cld.2011.03.006
    Back to article
  4. 4Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008; 48:335-52.
    FattovichGBortolottiFDonatoFNatural history of chronic hepatitis B: special emphasis on disease progression and prognostic factorsJ Hepatol2008 483355210.1016/j.jhep.2007.11.011
    Back to article
  5. 5Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim D Y, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011; 12:568-74.
    YangHIYuenMFChanHLHanKHChenPJKimD Yet alRisk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive scoreLancet Oncol2011 125687410.1016/S1470-2045(11)70077-8
    Back to article
  6. 6Loomba R, Liu J, Yang HI, Lee MH, Lu SN, Wang LY, et al. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013; 11:1636-45.
    LoombaRLiuJYangHILeeMHLuSNWangLYet alSynergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinomaClin Gastroenterol Hepatol2013 1116364510.1016/j.cgh.2013.04.043410077723669307
    Back to article
  7. 7El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365:1118-27.
    El-SeragHBHepatocellular carcinomaN Engl J Med2011 36511182710.1056/NEJMra100168321992124
    Back to article
  8. 8Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005; 54:1610-4.
    YuenMFYuanHJWongDKYuenJCWongWMChanAOet alPrognostic determinants for chronic hepatitis B in Asians: therapeutic implicationsGut2005 541610410.1136/gut.2005.065136177476815871997
    Back to article
  9. 9Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002; 347:168-74.
    YangHILuSNLiawYFYouSLSunCAWangLYet alHepatitis B e antigen and the risk of hepatocellular carcinomaN Engl J Med2002 3471687410.1056/NEJMoa01321512124405
    Back to article
  10. 10Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295:65-73.
    ChenCJYangHISuJJenCLYouSLLuSNet alRisk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA levelJAMA2006 295657310.1001/jama.295.1.6516391218
    Back to article
  11. 11Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012; 142: 1140-9.
    TsengTCLiuCJYangHCSuTHWangCCChenCLet alHigh levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV loadGastroenterology2012 1421140910.1053/j.gastro.2012.02.00722333950
    Back to article
  12. 12Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100:1134-43.
    YangHIYehSHChenPJ Iloeje UHJenCLSuJet alAssociations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinomaJ Natl Cancer Inst2008 10011344310.1093/jnci/djn243251816618695135
    Back to article
  13. 13Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010; 53: 348-56.
    PapatheodoridisGVLamperticoPManolakopoulosSLokAIncidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic reviewJ Hepatol2010 533485610.1016/j.jhep.2010.02.03520483498
    Back to article
  14. 14Wong GL, Chan HL, Chan HY, Tse PC, Tse YK, Mak CW, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology. 2013; 144:933-44.
    WongGLChanHLChanHYTsePCTseYKMakCWet alAccuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatmentGastroenterology2013 1449334410.1053/j.gastro.2013.02.00223415803
    Back to article
  15. 15Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, et al. PAGE-B: A risk score for hepatocellular carcinoma in Caucasians with chronic hepatitis B under a 5-year entecavir or tenofovir therapy. J Hepatol. 2016; 64:800-6.
    PapatheodoridisGDalekosGSypsaVYurdaydinCButiMGoulisJet alPAGE-B: A risk score for hepatocellular carcinoma in Caucasians with chronic hepatitis B under a 5-year entecavir or tenofovir therapyJ Hepatol2016 64800610.1016/j.jhep.2015.11.03526678008
    Back to article
  16. 16Jung KS, Kim SU, Song K, Park JY, Kim do Y, Ahn SH, et al. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. Hepatology. 2015; 62:1757-66.
    JungKSKimSUSongKParkJYKimdo YAhnSHet alValidation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapyHepatology2015 6217576610.1002/hep.2811526249025
    Back to article
  17. 17Lee HW, Yoo EJ, Kim BK, Kim SU, Park JY, Kim do Y, et al. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Am J Gastroenterol. 2014; 109:1241-9.
    LeeHWYooEJKimBKKimSUParkJYKimdo Yet alPrediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapyAm J Gastroenterol2014 1091241910.1038/ajg.2014.15724957159
    Back to article
  18. 18McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000; 32:842-6.
    McMahonBJBulkowLHarpsterASnowballMLanierASaccoFet alScreening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based studyHepatology2000 32842610.1053/jhep.2000.1791411003632
    Back to article
  19. 19Wong LL, Limm WM, Severino R, Wong LM. Improved survival with screening for hepatocellular carcinoma. Liver Transpl. 2000; 6:320-5.
    WongLLLimmWMSeverinoRWongLMImproved survival with screening for hepatocellular carcinomaLiver Transpl2000 6320510.1053/lv.2000.487510827233
    Back to article
  20. 20Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA. 2000; 283:2975-8.
    WelchHGSchwartzLMWoloshinSAre increasing 5-year survival rates evidence of success against cancer?JAMA2000 2832975810.1001/jama.283.22.297510865276
    Back to article
  21. 21Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clinical Oncol. 2004; 130:417-22.
    ZhangBHYangBHTangZYRandomized controlled trial of screening for hepatocellular carcinomaJ Cancer Res Clinical Oncol2004 1304172210.1007/s00432-004-0552-015042359
    Back to article
  22. 22Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53:1020-2.
    BruixJShermanMManagement of hepatocellular carcinoma: an updateHepatology2011 531020210.1002/hep.24199308499121374666
    Back to article
  23. 23Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010; 4: 439-74.
    OmataMLesmanaLATateishiRChenPJLinSMYoshidaHet alAsian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinomaHepatol Int2010 44397410.1007/s12072-010-9165-7290056120827404
    Back to article
  24. 24EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56: 908-43.
    EASL-EORTC clinical practice guidelines: management of hepatocellular carcinomaJ Hepatol2012 569084310.1016/j.jhep.2011.12.00122424438
    Back to article
  25. 25Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010; 4: 439-74.
    OmataMLesmanaLATateishiRChenPJLinSMYoshidaHet alAsian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinomaHepatol Int2010 44397410.1007/s12072-010-9165-7
    Back to article
  26. 26Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53:1020-2.
    BruixJShermanMManagement of hepatocellular carcinoma: an updateHepatology2011 531020210.1002/hep.24199
    Back to article
  27. 27EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56: 908-43.
    EASL-EORTC clinical practice guidelinesmanagement of hepatocellular carcinomaJ Hepatol 20125610.1016/j.jhep.2011.12.001
    Back to article
  28. 28Eltabbakh M, Zaghla H, Abdel-Razek W, Elshinnawy H, Ezzat S, Gomaa A, et al. Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. Med Oncol. 2015; 32:432. doi: 10.1007/s12032-014-0432-7.
    EltabbakhMZaghlaHAbdel-RazekWElshinnawyHEzzatSGomaaAet alUtility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited settingMed Oncol2015 32432 10.1007/s12032-014-0432-725502085
    Open DOIBack to article
  29. 29Paul SB, Sreenivas V, Gulati MS, Madan K, Gupta AK, Mukhopadhyay S, et al. Economic evaluation of a surveillance program of hepatocellular carcinoma (HCC) in India. Hepatol Int. 2008; 2:231-6.
    PaulSB eenivas VSr GulatiMSMadanKGuptaAKMukhopadhyaySet alEconomic evaluation of a surveillance program of hepatocellular carcinoma (HCC) in IndiaHepatol Int2008 2231610.1007/s12072-008-9054-5271684319669309
    Back to article
  30. 30Yuen MF, Lai CL. Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. Ann Oncol. 2003; 14:1463-7.
    YuenMFLaiCLScreening for hepatocellular carcinoma: survival benefit and cost-effectivenessAnn Oncol2003 141463710.1093/annonc/mdg40014504044
    Back to article
  31. 31World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. [online] 2013. [cited on 2016 Jan 15]. Available from: http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf
    World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection[online] 2013 cited on 2016 Jan 15 Available from http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf
    Back to article
  32. 32Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008; 26:6266-73.
    ZanettiARVanDamme PShouvalDThe global impact of vaccination against hepatitis B: a historical overviewVaccine2008 2662667310.1016/j.vaccine.2008.09.05618848855
    Back to article
  33. 33Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol. 2013; 8:371-80.
    LemoineMNayagamSThurszMViral hepatitis in resource-limited countries and access to antiviral therapies: current and future challengesFuture Virol2013 83718010.2217/fvl.13.11364623923662157
    Back to article
  34. 34Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009; 50:80-8.
    YuenMFTanakaYFongDYFungJWongDKYuenJCet alIndependent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis BJ Hepatol2009 5080810.1016/j.jhep.2008.07.02318977053
    Back to article
  35. 35Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010; 28:1660-5.
    WongVWChanSLMoFChanTCLoongHHWongGLet alClinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriersJ Clin Oncol2010 281660510.1200/JCO.2009.26.267520194845
    Back to article
  36. 36Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol. 2015; 62:363-70.
    PapatheodoridisGVDalekosGNYurdaydinCButiMGoulisJArendsPet alIncidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovirJ Hepatol2015 623637010.1016/j.jhep.2014.08.04525195548
    Back to article
  37. 37Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015; 64:1289-95.
    ArendsPSonneveldMJZoutendijkRCareyIBrownAFasanoMet alEntecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in CaucasiansGut2015 6412899510.1136/gutjnl-2014-30702325011935
    Back to article
  38. 38Abu-Amara M, Cerocchi O, Malhi G, Sharma S, Yim C, Shah H, et al. The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection. Gut. 2015.
    Abu-AmaraMCerocchiOMalhiGSharmaSYimCShahHet alThe applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infectionGut201510.1136/gutjnl-2014-30909925934760
    Back to article
  39. 39Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000; 15:1356-61.
    MericanIGuanRAmarapukaDAlexanderMJChutaputtiAChienRNet alChronic hepatitis B virus infection in Asian countriesJ Gastroenterol Hepatol2000 1513566110.1046/j.1440-1746.2000.0150121356.x11197043
    Back to article
  40. 40Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA. 1990; 263:1218-22.
    AlterMJHadlerSCMargolisHSAlexanderWJHuPYJudsonFNet alThe changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategiesJAMA1990 26312182210.1001/jama.263.9.1218
    Back to article
  41. 41Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus—large-scale analysis using a new genotyping method. J Infect Dis. 1997; 175:1285-93.
    LindhMAnderssonASGusdalAGenotypes, nt 1858 variants, and geographic origin of hepatitis B virus—large-scale analysis using a new genotyping methodJ Infect Dis1997 17512859310.1086/5164589180165
    Back to article
  42. 42Zhang H, Zhai Y, Hu Z, Wu C, Qian J, Jia W, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet. 2010; 42:755-8.
    ZhangHZhaiYHuZWuCQianJJiaWet alGenome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriersNat Genet2010 42755810.1038/ng.63820676096
    Back to article
  43. 43Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D. Severe liver fibrosis or cirrhosis: accuracy of US for detection—analysis of 300 cases. Radiology. 2003; 227:89-94.
    ColliAFraquelliMAndreolettiMMarinoBZuccoliEConteDSevere liver fibrosis or cirrhosis: accuracy of US for detection—analysis of 300 casesRadiology2003 227899410.1148/radiol.227202019312601199
    Back to article
  44. 44Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015; 61:292-302.
    XiaoGYangJYanLComparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysisHepatology2015 6129230210.1002/hep.2738225132233
    Back to article
  45. 45Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008; 134:960-74.
    Friedrich-RustMOngMFMartensSSarrazinCBojungaJZeuzemSet alPerformance of transient elastography for the staging of liver fibrosis: a meta-analysisGastroenterology2008 1349607410.1053/j.gastro.2008.01.03418395077
    Back to article
  46. 46Jung KS, Kim SU, Ahn SH, Park YN, Kim do Y, Park J Y, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011; 53:885-94.
    JungKSKimSUAhnSHParkYNKimdo YParkJ Yet alRisk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan)Hepatology2011 538859410.1002/hep.2412121319193
    Back to article
  47. 47Wong GL, Chan HL, Wong CK, Leung C, Chan CY, Ho PP, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014; 60:339-45.
    WongGLChanHLWongCKLeungCChanCYHoPPet alLiver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis BJ Hepatol2014 603394510.1016/j.jhep.2013.09.02924128413
    Back to article
  48. 48Branchi F, Conti CB, Baccarin A, Lampertico P, Conte D, Fraquelli M. Non-invasive assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol. 2014; 20:14568-80.
    BranchiFContiCBBaccarinALamperticoPConteDFraquelliMNon-invasive assessment of liver fibrosis in chronic hepatitis BWorld J Gastroenterol2014 20145688010.3748/wjg.v20.i40.14568420952425356021
    Back to article
  49. 49Kim BK, Kim HS, Park JY, Kim do Y, Ahn SH, Chon CY, et al. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One. 2012; 7:e41964.
    KimBKKimHSParkJYKimdo YAhnSHChonCYet alProspective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis BPLoS One2012 7e4196410.1371/journal.pone.0041964340705022848675
    Back to article
  50. 51Kim BK, Kim HS, Yoo EJ, Oh EJ, Park JY, Kim do Y, et al. Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. Hepatology. 2014; 60:1911-9.
    KimBKKimHSYooEJOhEJParkJYKimdo Yet alRisk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis testHepatology2014 601911910.1002/hep.2738925142433
    Back to article
  51. 52Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009; 50:80-8.
    YuenMFTanakaYFongDYFungJWongDKYuenJCet alIndependent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis BJ Hepatol2009 5080810.1016/j.jhep.2008.07.02318977053
    Back to article
  52. 53Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clinical Oncol. 2010; 28:1660-5.
    WongVWChanSLMoFChanTCLoongHHWongGLet alClinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriersJ Clinical Oncol2010 281660510.1200/JCO.2009.26.267520194845
    Back to article
  53. 54Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011; 12:568-74.
    YangHIYuenMFChanHLHanKHChenPJKimDYet alRisk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive scoreLancet Oncol2011 125687410.1016/S1470-2045(11)70077-8
    Back to article
  54. 55Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, et al. PAGE-B: a risk score for hepatocellular carcinoma in Caucasians with chronic hepatitis B under a 5-year entecavir or tenofovir therapy. J Hepatol. 2016: doi: 10.1016/j.jhep.2015.11.035.
    PapatheodoridisGDalekosGSypsaVYurdaydinCButiMGoulisJet alPAGE-B: a risk score for hepatocellular carcinoma in Caucasians with chronic hepatitis B under a 5-year entecavir or tenofovir therapyJ Hepatol2016 10.1016/j.jhep.2015.11.03526678008
    Open DOIBack to article
DOI: https://doi.org/10.5372/1905-7415.1001.459 | Journal eISSN: 1875-855X | Journal ISSN: 1905-7415
Journal RSS Feed
Language: English
Page range: 3 - 13
Published on: Jan 31, 2017
Published by: Chulalongkorn University
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year
Keywords:
Albumin,
antiviral therapy,
cirrhosis,
entecavir,
transient elastography
Related subjects:
Medicine,
Assistive professions, nursing,
Basic medical science,
Basic medical science, other,
Clinical medicine,
Clinical medicine, other

© 2017 Ken Liu, Grace Lai-Hung Wong, published by Chulalongkorn University
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 10 (2016): Issue 1 (February 2016)Next article